A startup company that’s found a unique niche in the exploding cannabis industry, Potbotics uses robotic technology to bring medical marijuana use into a new era of high-tech pharma.
Scientifically Adept - Platform Agnostic: Particle Sciences Positions Itself as a Bioavailability Tool for Most Dosage FormsJanuary 22, 2015 11:50 am | by Mike Auerbach, Editor In Chief | Comments
Particle Sciences, a drug development services company located in Bethlehem, Pennsylvania, has...
With new mAb drugs such as Kadcyla costing over 100,000 Euros per year, the price per patient...
Dr. Donna Nelson, the former scientific advisor to the hit-show “Breaking Bad” and president-elect of the American Chemical Society talks Hollywood, making meth, and the most urgent issue facing the chemical industry.
When present in pharmaceutical products, pyrogenic substances can prove harmful to humans by causing life threatening fevers. Therefore, testing of pharmaceutical products for pyrogens is critical to ensure patient safety.
Syrup extract found to make antibiotics more effective against bacteria.
Just as calibration needs to be part of your quality processes, it absolutely needs to be part of your asset performance management (APM) strategy as well.
Polls generally show that the majority of Americans are on board with the death penalty. In October 2014, Gallup reported that 63 percent of Americans were in favor of capital punishment while 33 percent were opposed.
Legacy Pharmaceutical Packaging, in St. Louis, Missouri is proud of its entrepreneurial spirit, its operational flexibility and technological expertise, and the breadth of packaging services it offers to its customers in a wide variety of segments of the healthcare industry.
The average cost of developing an approved therapy is around $4.3 billion dollars for companies with three or more approved therapies, according to an analysis completed by Forbes. Imagine, then, our surprise when we discovered a biotechnology company outside of New York City that had developed three approved therapies for an average cost of $0.7 billion dollars – less than 20 percent of the industry average.
Clean rooms are the standard for cGMP-compliant manufacturing, but the significant time and high costs of manufacturing and maintenance, as well as the lack of mobility, makes them difficult to justify.
As global demand for bottle-packaged pharmaceuticals grows, incremental upgrades in desiccant canister design yield substantial performance improvements.
Like so many industries, pharmaceutical processing is increasingly focused on improving the operational energy efficiency. One challenge that often stands in the way: cleanrooms. In these facilities, energy efficiency understandably takes a back seat to the mission of clean production. As a result, due to FDA-required filtration, high-performance processing machines and other factors, cleanrooms are energy intensive.
Dust has always been an unwanted byproduct of tablet manufacturing. In a perfect world, all powder would flawlessly flow into the hopper, and 100% of the product would emerge as finished tablets. In practice, though, most tablet presses are so inundated with dust after an eight-hour run that they form miniature snow piles on both sides of the feeder, and build-ups of material occur around the takeoff bar and recirculation channel.
Biosimilars have increasingly become an important and somewhat controversial topic in the healthcare space. Depending on who one speaks to, the opinion on biosimilars changes. However, there are certain truths that all stakeholders should keep in mind.
SAFC, a global supplier of a a wide range of services to the biopharm and pharmaceutical industry, has recently expanded their Madison, Wisconsin facilities to neighboring Verona to rev up their high-potency API manufacturing capabilities.
When it comes to the supply chain, business can be risky. A seminal survey of companies in various industries spanning 62 countries found 85% of respondents have experienced a supply chain disruption over the last 12 months, and 50% of companies had more than one disruption.
The development of new chemistry-based products for life science markets requires the expertise of talented researchers. However, these same researchers are typically not prepared to solve the many other critical problems necessary for successful commercialization.